您现在的位置: 首页  > 学术信息  > 正文

【院长论坛】Vasopressin: a novel target for the prevention and retardation of kidney disease?

发布日期:2013-06-09    浏览次数:
 

北京大学基础医学院

院长论坛

报告题目:  Vasopressin: a novel target for the prevention and retardation of kidney disease?

报告人:Dr Lise BANKIR

Directeur de Recherche Emeritus, INSERM, Paris, France

时间:2013613日上午10:00

地点:生化楼三楼中厅

主持人:杨宝学教授

报告人简介

Research
Abstract

Latest epidemiological studies suggest a role of  vasopressin in the pathogenesis of diabetes mellitus and metabolic disorders via activation of hepatic V1a and/or pancreatic islet V1b receptors. The first part of this lecture will describe the adverse effects of vasopressin, as revealed by clinical and experimental studies in kidney diseases, hypertension, diabetes and the metabolic syndrome. The second part will provide insights into vasopressin physiology and pathophysiology that may be relevant to the understanding of these adverse effects and that are linked to the excretion of concentrated nitrogen wastes and associated hyperfiltration.

Publications

Bankir L, Bouby N, Ritz E. Vasopressin: a novel target for the prevention and retardation of kidney disease? (Invited review) Nature reviews Nephrology 9(4):223-39. 2013

Perucca J, Bichet DG, Bardoux P, Bouby N, Bankir L: Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J. Am. Soc. Nephrol. 19: 1721–1731, 2008

Burnier M, Murielle Bochud M, Bankir L: Response to "Nocturnal Blood Pressure Fall Changes in Correlation With Urinary Sodium Excretion". Hypertension, 52: e11. Aug 2008 

欢迎各位老师及同学参加!